Reporting owner · CIK 0001221590
Bienaime Jean Jacques
SEC Form 4 history across 2 companies, 6 transactions and 4 filings.
DIRAscendis Pharma A S
Open-market transaction mix100% buys4 buys · 0 sales
Available history · May 26, 2026 – Aug 14, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
ASNDAscendis Pharma A S | Bienaime Jean JacquesDIR | P · buySEC filing ↗ | $222kView disclosure → | |
ASNDAscendis Pharma A S | Bienaime Jean JacquesDIR | P · buySEC filing ↗ | $270kView disclosure → | |
KROSKeros Therapeutics, Inc. | Bienaime Jean JacquesDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
KROSKeros Therapeutics, Inc. | Bienaime Jean JacquesDIR | A · grantSEC filing ↗ | $0View disclosure → | |
ASNDAscendis Pharma A S | Bienaime Jean JacquesDIR | P · buySEC filing ↗ | $47.8kView disclosure → | |
ASNDAscendis Pharma A S | Bienaime Jean JacquesDIR | P · buySEC filing ↗ | $47.2kView disclosure → |
Latest Form 4 facts
Quick context from source filings
Latest open-market transaction
buy at Ascendis Pharma A S on Aug 14, 2026 valued at $222,219.
Review SEC filingLatest sale
No open-market insider sale is available.
Monthly open-market activity
Last 3 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| May 2026 | 2 | 0 | $95,120.50 | $0.00 | $95,120.50 |
| Jun 2026 | 0 | 0 | $0.00 | $0.00 | $0.00 |
| Aug 2026 | 2 | 0 | $492,654.00 | $0.00 | $492,654.00 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Average P/S size$146.9K
Median P/S size$135K
Direct6
Indirect0
Aug 14, 2026buy
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
For every open-market buy (Form 4 code P, acquisition A) in the selected window, we take the closing price on the transaction date and 90 calendar days later, then compute the percentage change. The figures shown are the simple average and median of those per-buy returns.
- Scope is the available history shown in this profile.
- Only buys with a resolved price context are counted.
- Includes both positive and negative outcomes; gains and losses net out at the per-buy level.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
4 observations · May 26, 2026 – Aug 14, 2026. Window ends at the latest available report, not today.
Selected observation · Aug 14, 20262,900 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| May 26, 2026 | 200 | May 27, 2026 | View transaction |
| May 26, 2026 | 400 | May 27, 2026 | View transaction |
| Aug 14, 2026 | 2,000 | Aug 19, 2026 | View transaction |
| Aug 14, 2026 | 2,900 | Aug 19, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Bienaime Jean Jacques Insider Activity FAQ
SEC Form 4 context
Who is Bienaime Jean Jacques?
Bienaime Jean Jacques is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001221590.
Which companies has Bienaime Jean Jacques reported transactions for?
Ascendis Pharma A S, Keros Therapeutics, Inc.
When was Bienaime Jean Jacques's latest insider buy?
buy at Ascendis Pharma A S on Aug 14, 2026 valued at $222,219.
When was Bienaime Jean Jacques's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.